Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) EBIT Margin (2019 - 2025)

Historic EBIT Margin for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to 5735.95%.

  • Bioadaptives' EBIT Margin changed N/A to 5735.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 14410.84%, marking a year-over-year decrease of 127674800.0%. This contributed to the annual value of 4752.47% for FY2024, which is 39510600.0% down from last year.
  • As of Q3 2025, Bioadaptives' EBIT Margin stood at 5735.95%.
  • In the past 5 years, Bioadaptives' EBIT Margin ranged from a high of 415.47% in Q1 2024 and a low of 13774.52% during Q2 2024
  • Over the past 5 years, Bioadaptives' median EBIT Margin value was 2770.7% (recorded in 2022), while the average stood at 3514.14%.
  • As far as peak fluctuations go, Bioadaptives' EBIT Margin crashed by -113825100bps in 2024, and later soared by 51004300bps in 2025.
  • Quarter analysis of 5 years shows Bioadaptives' EBIT Margin stood at 4615.27% in 2021, then soared by 85bps to 685.29% in 2022, then fell by -25bps to 857.99% in 2023, then plummeted by -1505bps to 13774.52% in 2024, then surged by 58bps to 5735.95% in 2025.
  • Its EBIT Margin was 5735.95% in Q3 2025, compared to 8674.09% in Q2 2025 and 13774.52% in Q2 2024.